

Diagnosis and management of toxicity associated with the recreational use of nitrous oxide

Cyrille De Halleux MD, David N. Juurlink MD PhD

■ Cite as: *CMAJ* 2023 August 21;195:E1075-81. doi: 10.1503/cmaj.230196

Nitrous oxide (N₂O) has become a popular but dangerous recreational drug. Colloquially referred to as “laughing gas,” it was first used therapeutically in 1844 for patients undergoing dental surgery.¹ Although a weak anesthetic, it remains in use today, especially for pediatric and dental procedures.² Its recreational use is now recognized as a growing problem in many jurisdictions, including Australia^{3–5} and several European countries,⁶ particularly the United Kingdom.⁷ The true prevalence of recreational nitrous oxide use in Canada is unknown. However, 10% of all respondents and 15% of Canadian respondents to the 2021 Global Drug Survey reported having used nitrous oxide in the preceding year.⁸ This Internet-based survey provides insight about patterns of drug use, but respondents are not representative of the general population. Although no Canadian agencies track nitrous oxide use, evidence of substantial recreational use is apparent in Toronto and Montréal.^{9,10} Large quantities of nitrous oxide and associated paraphernalia are easily ordered online, with rapid shipping to major cities.¹¹ The drug’s popularity relates in part to its low cost, ease of access and perception of safety relative to other drugs.^{12,13}

Although acute, heavy use of nitrous oxide can occasionally cause death by asphyxiation,^{14,15} isolated, short-term use rarely leads to serious complications.¹⁶ Regular inhalation, however, can have serious and even devastating neurologic consequences. We discuss recreational nitrous oxide use and its toxicity, including methods and patterns of use, pathophysiology, clinical presentation, diagnosis and management. We draw on evidence from case reports, case series, surveys and mechanistic studies related to nitrous oxide use and its complications (Box 1).

What are the patterns of recreational use?

Most recreational users obtain nitrous oxide from cartridges of compressed gas intended for the preparation of whipped cream. Sometimes referred to as “Whippits,” these can be purchased in stores or online, often for less than \$1 per 8-g canister. Its low cost and ready availability may play a role in the observation that nitrous oxide is the most commonly used inhalant in adults. The

Key points

- Recreational use of nitrous oxide is a growing problem in many jurisdictions, including Canada.
- Although isolated, short-term use rarely leads to serious complications, chronic use can cause neurotoxicity that is often not fully reversible; cervical myelopathy, peripheral neuropathy and encephalopathy have been described.
- The pathophysiology of nitrous oxide toxicity results from functional vitamin B₁₂ deficiency.
- Elevated homocysteine and methylmalonic acid are potential biochemical markers for the diagnosis, and magnetic resonance imaging and nerve conduction studies can help further define the presentation.
- Cessation of nitrous oxide is the mainstay of treatment; supplementation with vitamin B₁₂ and methionine are recommended.

use of inhalants in general peaks around ages 13–14 years,¹⁷ with younger patients most often misusing solvent-based marking pens; however, the use of nitrous oxide peaks during early adulthood.¹⁸

Using a whipped cream dispenser or a simple opening device called a “cracker,” users release aliquots of gas into a balloon, which is then used to deliver “hits” of the drug by inhalation (Figure 1).¹⁹ Some users inhale directly from dispensers or crackers, although this can cause cold-related injury to the mouth and skin, because the expansion of compressed gas is an endothermic process.^{20,21} Rarely, users will employ a face mask connected to a nitrous oxide source or a bag placed over the head; this poses a high risk of asphyxiation and is the primary cause of death from nitrous oxide.^{6,22}

Upon inhalation, users experience euphoria, analgesia and disinhibition.^{13,19,23} The effects last only a few minutes, and repeated use is common when sustained effects are desired. Unlike therapeutic use, in which nitrous oxide mixed with oxygen is delivered in a monitored setting,²⁴ recreational use of pure nitrous oxide carries the risk of alveolar hypoxia, when users attempt to achieve and sustain concentrations needed to produce euphoria.^{16,25} Regular users commonly use dozens of cartridges daily,¹⁹ with case reports describing use of more than 500 cartridges per day.^{26,27}

Box 1: Evidence considered in this review

We searched PubMed from 1956 to 2022 for case reports, case series, surveys and mechanistic studies related to nitrous oxide use and its complications. We supplemented this by screening bibliographies of these articles and of a leading textbook of toxicology (Goldfrank's Toxicologic Emergencies¹⁶) to identify relevant articles regarding the pathophysiology, diagnosis and treatment of nitrous oxide complications.

What is the pathophysiology of nitrous oxide's toxic effects?

The toxic effects of nitrous oxide result primarily from a functional deficiency of vitamin B₁₂ (cobalamin) and are therefore chiefly neurologic and hematologic in nature. Vitamin B₁₂ functions as a coenzyme for 2 important enzymes: methionine synthase and methylmalonyl coenzyme A mutase (MCM).

Under normal circumstances, methionine synthase converts homocysteine to methionine and 5-methyltetrahydrofolate to tetrahydrofolate. These 2 processes are coupled, relying on the transfer of a methyl group by vitamin B₁₂ (as methylcobalamin; Figure 2). Nitrous oxide inactivates methylcobalamin by oxidizing its cobalt atom, effectively inhibiting methionine synthase. This impairs production of both methionine and tetrahydrofolate, which play key roles in the synthesis of myelin, as well as purines and pyrimidines (Figure 2). Nitrous oxide–induced neurotoxicity results primarily from impaired myelin synthesis, while megaloblastic anemia and other hematologic effects reflect the naturally high turnover of hematologic cells, a process that requires DNA and is therefore hampered by insufficient availability of purines and pyrimidines.^{24,28,29}

Prolonged nitrous oxide use also inhibits MCM. In mitochondria, MCM catalyzes the conversion of methylmalonyl-CoA to

succinyl-CoA, which then enters the Krebs cycle. The activity of MCM requires the coenzyme adenosylcobalamin (AdoCbl), a different form of vitamin B₁₂ from that oxidized by nitrous oxide. The exact mechanism of MCM inhibition by nitrous oxide is unclear but may reflect the observation that oxidized methylcobalamin is more readily excreted, reducing overall stores of vitamin B₁₂, mitochondrial AdoCbl and, subsequently, MCM activity in neural cells.^{30,31} The resulting accumulation of methylmalonic acid can serve as a sensitive diagnostic marker, but the extent to which MCM inhibition contributes to the clinical manifestations of vitamin B₁₂ deficiency remains unclear.

Other complementary hypotheses to explain the neurotoxicity of nitrous oxide include N-methyl-D-aspartate (NMDA) antagonism,^{32,33} dysregulation of cytokines and growth factors that regulate myelin integrity,³⁴ and hypoxia resulting from prolonged, heavy nitrous oxide use.^{35–37}

What are the consequences of chronic nitrous oxide use?

The acute and chronic complications of recreational nitrous oxide use are summarized in Table 1.

Neurologic manifestations

Neurologic abnormalities are the most prominent features of chronic nitrous oxide exposure, with 3 well-described presentations.^{22,28,38–40} The most commonly reported syndrome is myelopathy, generally in the form of subacute combined degeneration of the cervical spine. The second most commonly reported presentation is a peripheral sensorimotor neuropathy that predominantly affects the motor nerves.⁴¹ A third presentation is encephalopathy, which appears to be less common and is easily overlooked and often presents with new-onset psychiatric symptoms.




Figure 1: Apparatus for recreational nitrous oxide use. The nitrous oxide cartridge (B) is placed in a “cracker” (A), which punctures the cartridge, releasing the gas into the balloon (C).

The distinction between myelopathy and peripheral neuropathy can sometimes be challenging, and patients with nitrous oxide neurotoxicity often exhibit both. They commonly present with bilateral paresthesia, weakness and gait disturbances. The lower limbs tend to be more severely affected, with isolated lower limb abnormalities found in as many as a third of patients.³⁹ Common physical findings include reduced power and decreased sensation; pain and temperature sensation are more commonly impaired than vibration and proprioception, although abnormalities of both are frequent.⁴¹ Hypo- or hyperreflexia may be present, depending on whether peripheral nerves or the spinal cord are more prominently involved.³⁹ Features of neurogenic bladder, such as urinary retention or incontinence, are present in a minority of patients. Other potential findings include ataxia, Romberg sign, Lhermitte sign and Babinski sign.^{22,38,39}

Neurologic symptoms often develop acutely or subacutely after weeks to months of nitrous oxide use.²⁸ Rarely, patients present after nitrous oxide anesthesia, with symptoms developing gradually in the weeks thereafter, mimicking the presentation of chronic recreational users.^{38,42} These patients tend to be

Table 1: Complications of recreational nitrous oxide use

Type of complication	Clinical consequences
Acute	Altered cognition Hypoxemia Death by asphyxia (rare) Cold-related injury: e.g., mouth, hands
Chronic	Peripheral neuropathy <ul style="list-style-type: none"> Bilateral paresthesia and weakness, gait disturbances, hyporeflexia Myelopathy (subacute combined degeneration) <ul style="list-style-type: none"> Bilateral numbness, weakness, gait disturbances, hyperreflexia, urinary retention, incontinence Encephalopathy (rare) <ul style="list-style-type: none"> Behavioural changes, paranoia, delusions, hallucinations and other psychiatric symptoms Anemia Skin hyperpigmentation (rare) Thrombosis (rare)




Figure 2: Interaction between nitrous oxide (N₂O) and vitamin B₁₂ metabolic functions. (A) Methionine synthase (MS) converts homocysteine to methionine and 5-methyltetrahydrofolate (methyl-THF) to tetrahydrofolate (THF). Methylcobalamin (the methyl form of vitamin B₁₂) is an essential coenzyme in this process. Nitrous oxide quickly and irreversibly oxidizes the cobalt atom of methylcobalamin, rendering it inactive. The resulting inhibition of MS impairs folate activity and methionine synthesis, which are essential for DNA production and myelin integrity. It also leads to an increase in homocysteine. Methionine synthase inhibition largely underlies the neurotoxicity of N₂O. (B) Methylmalonyl Co-A mutase converts methylmalonyl-CoA to succinyl-CoA, which then enters the Krebs cycle. Adenosylcobalamin (ado-B₁₂; adenosyl form of vitamin B₁₂) is a cofactor for methylmalonyl coenzyme A mutase (MCM). Prolonged use of N₂O impairs the activity of MCM by unclear mechanisms. This increases methylmalonic acid concentration, which can be measured as a biomarker in patients with neurotoxicity secondary to N₂O use. Note: white boxes = enzyme; green boxes = coenzyme of vitamin B₁₂; red jagged circle = inhibition of enzyme activity; red “X” = interruption of the metabolic pathway.

older and many have marginal vitamin B₁₂ stores at baseline, rendering them more susceptible to the effects of nitrous oxide.^{43–45} In a minority of cases, encephalopathy is present, with reported symptoms including paranoia, delusions, hallucinations and behavioural change.^{22,38,40,46}

Dose-toxicity association

Unsurprisingly, neurologic complications are more common after repeated exposures. A survey of 16 124 recreational nitrous oxide users showed a strong association between the degree of exposure and the presence of neurologic symptoms.⁴⁷ Among 76 regular users with neurologic symptoms, the median duration of use was 8 months, and the median exposure was 25 cartridges daily (interquartile range 8–85).³⁸ However, patient factors such as baseline vitamin B₁₂ status influence both the susceptibility to neurologic symptoms and the temporal course of their development.^{38,48,49} Although no safe lower limit of exposure has been defined, complications after short-term use appear to be exceedingly rare. A recent systematic review found only 39 reported cases of neurotoxicity after nitrous oxide anesthesia.^{50,51}

Other manifestations

Because nitrous oxide renders vitamin B₁₂ nonfunctional, it can also cause hematologic abnormalities similar to those seen in pernicious anemia. Inhalation of 50% nitrous oxide for 1 hour can cause megaloblastic changes on bone marrow biopsy in susceptible patients, with similar features appearing after 12 hours of exposure in people with normal vitamin B₁₂ stores.^{16,52} Macrocytic anemia is evident in 35%–50% of chronic users,^{38,39} while other features of vitamin B₁₂ deficiency, such as leukopenia, hypersegmented neutrophils and thrombocytopenia, appear to be less common.^{52–55}

Skin hyperpigmentation is also described,⁵⁶ typically involving the dorsal aspects of the fingers and toes with maculopapular lesions on the trunk.⁵⁷ In a series of 66 patients with nitrous oxide–related neurologic symptoms, dermatological findings were found in only 4 patients.⁵⁸

Because impairment of methionine synthetase results in homocysteine elevation (Figure 2), a known risk factor for vascular disease, arterial and venous thrombotic events are theoretical complications of nitrous oxide use.^{59,60} No such effects were

seen in the largest randomized controlled trial of nitrous oxide use in anesthesia,⁵¹ but these findings may not be generalizable to chronic users. A recent systematic review identified 14 reports of arterial or venous thromboembolism in young people with prolonged nitrous oxide use and no other obvious risk factors for thromboembolism.⁶¹ Most of these patients also had hyperhomocysteinemia.

What is the approach to making a diagnosis?

Nitrous oxide toxicity should be considered in the differential for all patients with signs and symptoms of peripheral neuropathy, myelopathy or encephalopathy, especially those who are younger. A history of nitrous oxide exposure, and heavy use in particular, is necessary to support the diagnosis, which highlights the importance of taking a comprehensive history of drug and substance use. When consistent clinical features and a history of heavy nitrous oxide exposure are both present, biochemical testing for functional vitamin B₁₂ deficiency (homocysteine, methylmalonic acid) can confirm the diagnosis as described below (Table 2). Nervous system involvement should be further characterized with magnetic resonance imaging (MRI) and nerve conduction studies.^{28,38,50}

Biochemical testing

A low vitamin B₁₂ concentration is seen in 54%–72% of patients with neurologic complications from nitrous oxide exposure,^{22,38,39} and is especially likely among those who develop symptoms after shorter exposures, presumably reflecting increased susceptibility.³⁸ In chronic users, low vitamin B₁₂ concentrations may reflect hastened elimination.^{31,34} Homocysteine and methylmalonic acid accumulate as a result of reduced enzymatic activity (Figure 2), and at least one is elevated in more than 90% of patients.^{38,62,63} Therefore, these markers are more sensitive than vitamin B₁₂ concentrations, which remain normal in a substantial proportion of users despite neurotoxicity. Some users take supplemental vitamin B₁₂ in an effort to prevent neurotoxicity, which can lead to normal levels of these biomarkers; this may falsely reassure clinicians but does not fully protect against the neurologic complications of nitrous oxide use.^{64–66}

Table 2: Investigations for patients suspected of having nitrous oxide toxicity

Investigation type	Finding
Vitamin B ₁₂	Low (50%–75%) or normal (25%–50%) in patients with neurologic symptoms
Homocysteine	Increased
Methylmalonic acid	Increased
MRI spine	If myelopathy is present: hyperintensities in T ₂ , often at the C3–C4 with caudal extension in severe cases
Nerve conduction studies	Abnormal in most patient with symptoms <ul style="list-style-type: none"> • Axonal degeneration with or without demyelination (common) • Isolated demyelination without axonal degeneration (rare)
Note: MRI = magnetic resonance imaging.	




Figure 3: Inverted “V” sign of subacute combined degeneration. T_2 axial view of the spinal cord in a patient with extensive recreational use of nitrous oxide. Symmetric bilateral hyperintensities in the posterior cords (yellow arrow). Case courtesy of Jay Gajera, Radiopaedia.org, rID: 83938.

Imaging

Magnetic resonance imaging of the spine is the preferred modality for the identification of myelopathy, revealing T_2 hyperintensities in as many as two-thirds of patients with neurologic symptoms.^{38,39} A characteristic finding of subacute combined degeneration of the cord is the inverted “V” sign, corresponding to bilateral and symmetric T_2 hyperintensities in the dorsal columns (Figure 3). This is typically most prominent in the cervical cord but can also be seen in the thoracic cord, in severe cases.^{38,39}

Although MRI of the brain is often normal, white matter changes are sometimes seen in patients with neuropsychiatric symptoms, typically involving the frontal lobes.^{67,68} In a series of 110 cases of symptomatic recreational nitrous oxide users, frontal lobe demyelination was evident in 3 of 11 patients who underwent brain MRI.³⁹

Nerve conduction studies

Nerve conduction studies are abnormal in most symptomatic patients.^{22,28,39} The most common abnormalities are axonal degeneration, with or without demyelination, with isolated demyelination present in a minority of patients. In contrast to patients with quantitative vitamin B₁₂ deficiency not caused by nitrous oxide, who tend to have more prominent sensory abnormalities, nitrous oxide users often exhibit more pronounced motor dysfunction.⁴¹

How should patients be treated?

The mainstay of treatment is cessation of nitrous oxide use. Vitamin B₁₂ supplementation should also be given, sometimes in combination with methionine, although the evidence supporting efficacy is limited (Box 2).¹⁶ Given its favourable safety profile, we suggest intramuscular or subcutaneous injection of 1000 µg vitamin B₁₂ daily for 1 to 2 weeks, followed by

Box 2: Treatment of patients with nitrous oxide toxicity

- Cessation of exposure: Consider addiction medicine expertise and psychiatric, psychologic and social support
- B₁₂ (cobalamin): 1000 µg intramuscularly daily for 1–2 weeks, followed by 1000 µg weekly or 2000 µg oral daily until resolution of symptoms
- Methionine: 1 g oral 3 times daily for at least 4–6 weeks or significant improvement of symptoms
- Other: Rehabilitation for neurologic disabilities
- Other: Do not administer folate before B₁₂ supplementation

weekly doses of 1000 µg parentally or daily doses of 2000 µg by mouth, until resolution of symptoms.^{16,69,70} We also suggest supplemental oral methionine 1 g, 3 times daily (for at least 4–6 weeks or significant improvement of symptoms), which is likewise safe.^{40,48,67,71} Folate supplementation is unlikely to benefit the patient and should not be given before vitamin B₁₂ repletion because of the potential for exacerbation of symptoms and delayed recovery.^{29,48,72} Physical rehabilitation and psychological and social supports may be required in selected cases.

Prognosis

Although the prognosis is variable, most (95%–97%) patients display at least partial improvement, but more than one-third of patients admitted to hospital have residual neurologic symptoms even after months of treatment.^{22,39,40} The onset of improvement may be gradual, sometimes with little to no change during the first month of treatment but significant improvement in the months thereafter, reflecting the importance of sustained avoidance of nitrous oxide.^{28,39}

Prevention

The public health response to nitrous oxide use is beyond the scope of this review.⁶ However, some actions can be taken by physicians to limit short- and long-term complications. To minimize short-term risks of nitrous oxide, we suggest counselling against the use of methods that risk asphyxiation (e.g., affixed masks and bags over the head)²² and inhalation directly from cartridges^{20,21} to reduce the risks of asphyxiation and thermal injury, respectively. Use during safety-sensitive activities like driving should obviously be discouraged.

The prevention of long-term complications requires stopping or at least reducing nitrous oxide use. In addition to education, some users may benefit from formal addiction medicine expertise, and psychological, social and peer support. In heavy users who do not promptly cease nitrous oxide, clinicians should consider suggesting prophylactic vitamin B₁₂ supplements. This may delay the onset of symptoms and afford the patient time to reconsider the practice or seek treatment for substance use disorder.⁴⁸ In such cases, it must be understood that neurotoxicity is well described despite use of B₁₂ supplements, and that the only reliable way to prevent morbidity is cessation of nitrous oxide use.^{73,74}

Box 3: Unanswered questions

- What are the optimal dose and duration of vitamin B₁₂ and methionine for the treatment of nitrous oxide neurotoxicity?
- Can individual risk of neurotoxicity after short- and long-term exposure be predicted?
- What pathophysiologic processes underlie the quantitative vitamin B₁₂ deficiency and inhibition of methylmalonyl coenzyme A mutase in patients with prolonged exposure to nitrous oxide?

Conclusion

The low cost of and ease of access to nitrous oxide make it a popular recreational drug, especially among younger people. It can cause functional vitamin B₁₂ deficiency and is an easily overlooked cause of neurologic abnormalities, typically myelopathy, peripheral neuropathy or encephalopathy, sometimes accompanied by hematologic abnormalities. Clinicians should enquire about nitrous oxide use in patients with unexplained findings suggestive of vitamin B₁₂ deficiency or other compatible neurologic symptoms. Questions for future research are listed in Box 3.

References

- Erving HW. The discoverer of anaesthesia: Dr. Horace Wells of Hartford. *Yale J Biol Med* 1933;5:421-30.
- Buhre W, Disma N, Hendrickx J, et al. European Society of Anaesthesiology Task Force on Nitrous Oxide: a narrative review of its role in clinical practice. *Br J Anaesth* 2019;122:587-604.
- National Drug Strategy Household Survey 2019. Drug Statistics series no 32, PHE 270. Canberra AIHW (Australia): Australian Institute of Health and Welfare; 2020.
- Nitrous oxide: uses, impacts and risks. Victoria (Australia): Alcohol and Drug Foundation; 2023. Available: <https://adf.org.au/insights/nitrous-oxide/> (accessed 2023 May 30).
- Symons B. Warning over rise in nitrous oxide abuse as service stations sell potentially deadly 'nangs' to teenagers [news release]. *ABC News* 2023 Feb. 21. Available: <https://www.abc.net.au/news/2023-02-21/calls-to-regulate-nitrous-oxide-nang-sales-after-death/101997190> (accessed 2023 May 30).
- Recreational use of nitrous oxide: a growing concern for Europe [rapid communication]. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2022 Nov. 21. Available: https://www.emcdda.europa.eu/publications/rapid-communication/recreational-use-nitrous-oxide-growing-concern-europe_en (accessed 2023 Jan. 10).
- Advisory Council on the Misuse of Drugs. Nitrous oxide: updated harms assessment. London (UK): Public Health England; updated 2023 June 22. Available: <https://www.gov.uk/government/publications/nitrous-oxide-updated-harms-assessment> (accessed 2023 Mar. 27).
- Winstock AR, Maier LJ, Zhuparris A, et al. Global Drug Survey (GDS) 2021 key findings report. London (UK): Global Drug Survey; 2021. Available: https://www.globaldrugsurvey.com/wp-content/uploads/2021/12/Report2021_global.pdf (accessed 2023 Nov. 1).
- Lahey J. Why so many empty nitrous oxide cartridges at Yonge and Sheppard? *Toronto Star* 2020 Feb. 7. Available: <https://www.thestar.com/news/gta/the-fixer/2020/02/07/why-so-many-empty-nitrous-oxide-cartridges-at-yonge-and-sheppard.html> (accessed 2023 May 31).
- Gacon A. Le gaz hilarant: une drogue assez prise au sérieux au Canada? *Radio-Canada* 2023 Mar. 1. Available: <https://ici.radio-canada.ca/nouvelle/1959799/gaz-hilarant-droque-canada-cadre#:~:text=Des%20risques%20d%C3%A8s%20la%20premi%C3%A8re,faire%20de%20la%20cr%C3%A8me%20fouett%C3%A9e> (accessed 2023 May 31).
- GreatWhip whipped cream chargers 1200 count/2 boxes 8.2 grams overstocked whip cream cartridges with all dispenser. Amazon. Available: <https://www.amazon.com/GreatWhip-Whipped-Chargers-Overstocked-Cartridges/dp/B09SYQSH6L> (accessed 2023 May 31).
- Kaar SJ, Ferris J, Waldron J, et al. Up: the rise of nitrous oxide abuse. An international survey of contemporary nitrous oxide use. *J Psychopharmacol* 2016;30:395-401.
- Nabben T, Weijs J, van Amsterdam J. Problematic use of nitrous oxide by young Moroccan-Dutch adults. *Int J Environ Res Public Health* 2021;18:5574.
- Bäckström B, Johansson B, Eriksson A. Death from nitrous oxide. *J Forensic Sci* 2015;60:1662-5.
- DiMaio VJ, Garriott JC. Four deaths resulting from abuse of nitrous oxide. *J Forensic Sci* 1978;23:169-72.
- Guo CJ, Kaufman BS. Chapter 65: Inhalational anesthetics. In: Nelson LS, Howland M, Lewin NA, et al., editors. *Goldfrank's Toxicologic Emergencies*. 11th ed. New York: McGraw Hill; 2019:1012-4.
- Johnston LD, Miech RA, O'Malley PM, et al. Monitoring the future national survey results on drug use, 1975–2020: overview, key findings on adolescent drug use. Ann Arbor (MI): Institute for Social Research, University of Michigan; 2021. Available: <https://eric.ed.gov/?id=ED611736> (accessed 2023 Nov. 1).
- 2021 NSDUH (National Survey on Drug Use and Health) detailed tables. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2023. Available: <https://www.samhsa.gov/data/report/2021-nsduh-detailed-tables> (accessed 2023 May 31).
- Erowid F. Prevalence of nitrous oxide use and practices: a survey of Erowid.org visitors. Erowid; 2009. Available: https://erowid.org/chemicals/nitrous/nitrous_info7.shtml (accessed 2023 Nov. 1).
- Quax MLJ, Van Der Steenhoven TJ, Bronkhorst MWGA, et al. Frostbite injury: an unknown risk when using nitrous oxide as a party drug. *Acta Chir Belg* 2022;122:140-3.
- Baran KC, de Vries AM. Frostbite of the mouth after partying. *BMJ* 2021;373.
- Garakani A, Jaffe RJ, Savla D, et al. Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: a systematic review of the case literature. *Am J Addict* 2016;25:358-69.
- Beckman NJ, Zacny JP, Walker DJ. Within-subject comparison of the subjective and psychomotor effects of a gaseous anesthetic and two volatile anesthetics in healthy volunteers. *Drug Alcohol Depend* 2006;81:89-95.
- Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. *Anesthesiology* 2008;109:707-22.
- Potocka-Banas B, Majdanik S, Dutkiewicz G, et al. Death caused by addictive inhalation of nitrous oxide. *Hum Exp Toxicol* 2011;30:1875-7.
- Lewis B, Nelson G, Vu T, et al. No laughing matter: myeloneuropathy due to heavy chronic nitrous oxide abuse. *Am J Emerg Med* 2021;46:799.e1-2.
- Swart G, Blair C, Lu Z, et al. Nitrous oxide-induced myeloneuropathy. *Eur J Neurol* 2021;28:3938-44.
- Largeau B, Karam A, Potey C, et al. Myeloneuropathy induced by recreational nitrous oxide use with variable exposure levels. *Eur J Neurol* 2022;29:2173-80.
- Scott JM, Weir DG. The methyl folate trap. A physiological response in man to prevent methyl group deficiency in kwashiorkor (methionine deficiency) and an explanation for folic-acid induced exacerbation of subacute combined degeneration in pernicious anaemia. *Lancet* 1981;2:337-40.
- Riedel B, Fiskerstrand T, Refsum H, et al. Co-ordinate variations in methylmalonyl-CoA mutase and methionine synthase, and the cobalamin cofactors in human glioma cells during nitrous oxide exposure and the subsequent recovery phase. *Biochem J* 1999;341:133-8.
- Kondo H, Osborne ML, Kolhouse JF, et al. Nitrous oxide has multiple deleterious effects on cobalamin metabolism and causes decreases in activities of both mammalian cobalamin-dependent enzymes in rats. *J Clin Invest* 1981;67:1270-83.
- Savage S, Ma D. The neurotoxicity of nitrous oxide: the facts and "putative" mechanisms. *Brain Sci* 2014;4:73-90.
- Jevtovic-Todorovic V, Todorovic SM, Mennerick S, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. *Nat Med* 1998;4:460-3.
- Hathout L, El-Saden S. Nitrous oxide-induced B₁₂ deficiency myelopathy: perspectives on the clinical biochemistry of vitamin B₁₂. *J Neurol Sci* 2011;301:1-8.
- Vodovar D, Care W, Batisse A, et al. Vitamin B₁₂ inactivation may not be the only cause of acquired peripheral neuropathy in chronic nitrous oxide users. *Br J Clin Pharmacol* 2022;88:356-7.
- Ozge A, Atis S, Sevim S. Subclinical peripheral neuropathy associated with chronic obstructive pulmonary disease. *Electromyogr Clin Neurophysiol* 2001;41:185-91.
- Mayer P, Dematteis M, Pépin JL, et al. Peripheral neuropathy in sleep apnea. A tissue marker of the severity of nocturnal desaturation. *Am J Respir Crit Care Med* 1999;159:213-9.
- Oussalah A, Julien M, Levy J, et al. Global burden related to nitrous oxide exposure in medical and recreational settings: a systematic review and individual patient data meta-analysis. *J Clin Med* 2019;8:551.

39. Yu M, Qiao Y, Li W, et al. Analysis of clinical characteristics and prognostic factors in 110 patients with nitrous oxide abuse. *Brain Behav* 2022;12:e2533.
40. Marsden P, Sharma AA, Rotella J-A. Review article: Clinical manifestations and outcomes of chronic nitrous oxide misuse — a systematic review. *Emerg Med Australas* 2022;34:492-503.
41. Tani J, Weng H-Y, Chen H-J, et al. Elucidating unique axonal dysfunction between nitrous oxide abuse and vitamin B₁₂ deficiency. *Front Neurol* 2019;10:704.
42. Duan EH, Adhikari NKJ, D'Aragon F, et al.; Canadian Critical Care Trials Group. Management of acute respiratory distress syndrome and refractory hypoxemia. A multicenter observational study. *Ann Am Thorac Soc* 2017;14:1818-26.
43. Somyreddy K, Kothari M. Nitrous oxide induced sub-acute combined degeneration of spinal cord: a case report. *Electromyogr Clin Neurophysiol* 2008;48:225-8.
44. Marié RM, Le Biez E, Busson P, et al. Nitrous oxide anesthesia-associated myelopathy. *Arch Neurol* 2000;57:380-2.
45. Kinsella LJ, Green R. 'Anesthesia paresthetica': nitrous oxide-induced cobalamin deficiency. *Neurology* 1995;45:1608-10.
46. Chien W-H, Huang M-C, Chen L-Y. Psychiatric and other medical manifestations of nitrous oxide abuse: implications from case series. *J Clin Psychopharmacol* 2020;40:80-3.
47. Winstock AR, Ferris JA. Nitrous oxide causes peripheral neuropathy in a dose dependent manner among recreational users. *J Psychopharmacol* 2020;34:229-36.
48. van der Westhuyzen J, Fernandes-Costa F, Metz J. Cobalamin inactivation by nitrous oxide produces severe neurological impairment in fruit bats: protection by methionine and aggravation by folates. *Life Sci* 1982;31:2001-10.
49. Dinn JJ, McCann S, Wilson P, et al. Animal model for subacute combined degeneration. *Lancet* 1978;2:1154.
50. Patel KK, Mejia Munne JC, Gunness VRN, et al. Subacute combined degeneration of the spinal cord following nitrous oxide anesthesia: a systematic review of cases. *Clin Neurol Neurosurg* 2018;173:163-8.
51. Myles PS, Leslie K, Chan MTV, et al.; ANZCA Trials Group for the ENIGMA-II investigators. The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): a randomised, single-blind trial. *Lancet* 2014;384:1446-54.
52. Amos RJ, Amess JA, Hinds CJ, et al. Incidence and pathogenesis of acute megaloblastic bone-marrow change in patients receiving intensive care. *Lancet* 1982;2:835-8.
53. Lassen HC, Henriksen E, Neukirch F, et al. Treatment of tetanus; severe bone-marrow depression after prolonged nitrous-oxide anaesthesia. *Lancet* 1956;270:527-30.
54. Blanco G, Peters HA. Myeloneuropathy and macrocytosis associated with nitrous oxide abuse. *Arch Neurol* 1983;40:416-8.
55. Lai Y, Cheng J, Yang Z. Appearance of hypersegmented neutrophils in the peripheral blood associated with subacute combined degeneration of the spinal cord due to nitrous oxide abuse. *Br J Haematol* 2021;194:227.
56. Kannan R, Ng MJM. Cutaneous lesions and vitamin B₁₂ deficiency: an often-forgotten link. *Can Fam Physician* 2008;54:529-32.
57. Chiang T-T, Hung C-T, Wang W-M, et al. Recreational nitrous oxide abuse-induced vitamin B₁₂ deficiency in a patient presenting with hyperpigmentation of the skin. *Case Rep Dermatol* 2013;5:186-91.
58. Fang X, Li W, Gao H, et al. Skin hyperpigmentation: a rare presenting symptom of nitrous oxide abuse. *Clin Toxicol (Phila)* 2020;58:476-81.
59. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. *Arch Intern Med* 1998;158:2101-6.
60. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. *JAMA* 2002;288:2015-22.
61. Oulkadi S, Peters B, Vliegen A-S. Thromboembolic complications of recreational nitrous oxide (ab)use: a systematic review. *J Thromb Thrombolysis* 2022;54:686-95.
62. Metz J. Cobalamin deficiency and the pathogenesis of nervous system disease. *Annu Rev Nutr* 1992;12:59-79.
63. Deacon R, Lumb M, Perry J, et al. Selective inactivation of vitamin B₁₂ in rats by nitrous oxide. *Lancet* 1978;2:1023-4.
64. Pugliese RS, Slagle EJ, Oettinger GR, et al. Subacute combined degeneration of the spinal cord in a patient abusing nitrous oxide and self-medicating with cyanocobalamin. *Am J Health Syst Pharm* 2015;72:952-7.
65. Morris N, Lynch K, Greenberg SA. Severe motor neuropathy or neuronopathy due to nitrous oxide toxicity after correction of vitamin B₁₂ deficiency. *Muscle Nerve* 2015;51:614-6.
66. Wijesekera NT, Davagnanam I, Miskiel K. Subacute combined cord degeneration: a rare complication of nitrous oxide misuse. A case report. *Neuroradiol J* 2009;22:194-7.
67. Chiew AL, Raubenheimer JE, Berling I, et al. Just 'nanging' around: harmful nitrous oxide use — a retrospective case series and review of Internet searches, social media posts and the coroner's database. *Intern Med J* 2022;52:1724-32.
68. Thompson AG, Leite MI, Lunn MP, et al. Whippits, nitrous oxide and the dangers of legal highs. *Pract Neurol* 2015;15:207-9.
69. Stabler SP. Vitamin B₁₂ deficiency. *N Engl J Med* 2013;368:2041-2.
70. Kuzminski AM, Del Giacco EJ, Allen RH, et al. Effective treatment of cobalamin deficiency with oral cobalamin. *Blood* 1998;92:1191-8.
71. Stacy CB, Di Rocco A, Gould RJ. Methionine in the treatment of nitrous-oxide-induced neuropathy and myeloneuropathy. *J Neurol* 1992;239:401-3.
72. Reynolds EH. The risks of folic acid to the nervous system in vitamin B₁₂ deficiency: rediscovered in the era of folic acid fortification policies. *J Neurol Neurosurg Psychiatry* 2017;88:1097-8.
73. Blair C, Tremonti C, Edwards L, et al. Vitamin B₁₂ supplementation futile for preventing demyelination in ongoing nitrous oxide misuse. *Med J Aust* 2019;211:428-28.e1.
74. Temple C, Horowitz BZ. Nitrous oxide abuse induced subacute combined degeneration despite patient initiated B12 supplementation. *Clin Toxicol (Phila)* 2022;60:872-5.

Competing interests: David Juurlink has received reimbursement for travel costs for presentations and scientific meetings from the Canadian Institutes of Health Research, Stanford University and Texas Tech University Health Sciences Centre. No other competing interests were declared.

This article has been peer reviewed.

Affiliations: Departments of Medicine, Pediatrics, and Health Policy, Management and Evaluation (Juurlink), University of Toronto; Ontario Poison Centre (De Halleux, Juurlink); Sunnybrook Research Institute (Juurlink), Toronto, Ont.; ICES (Juurlink), Toronto, Ont.; Centre Antipoison du Québec (De Halleux), Québec, Que.

Contributors: Both authors contributed to the conception and design of the work, drafted the manuscript, revised it critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>

Acknowledgement: The authors thank Steven Curry for helpful comments on an earlier draft of this manuscript.

Correspondence to: David Juurlink, david.juurlink@ices.on.ca